Yisheng Pharmaceutical has received a risk control notice from the Jilin Medical Products Administration. Due to serious defects in the Bujin Tablets product, the production lines for Shengmai Injection and Bujin Tablets have been suspended from production and sales. In 2025, Bujin Tablets accounted for 7.65% of the company's total revenue, while Shengmai Injection accounted for 0.01%. The company has initiated a Level 3 recall for Bujin Tablets, has not yet received any reports of related adverse safety events, and will actively push forward with corrective actions.
Jilin Jian Yisheng Pharmaceutical Co LtdJilin Medical Products Administration issued risk control notice suspending production and sales of two products due to serious defects.